Skip to main content
Clinical Trials/EUCTR2010-024272-26-IT
EUCTR2010-024272-26-ITActive, not recruitingNot Applicable

Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure

IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS0 sitesStarted: March 20, 2012Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Signed informed consent • Age> 18 years • Diagnosis of glauocoma or ocular hypertension. The definition of glaucoma or ocular hypertension is based on the guidelines of the 'European Glaucoma Society • Patients newly diagnosed (Ocular hypertension and glaucoma) and never treated with ocular hypotensive drugs with any value tonometer and patients with OHT and POAG in ocular hypotensive drug therapy alone and with IOP <22mmHg at the screening visit.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

  • Inability to sign informed consent • Ocular conditions that can interfere with the results of the study • Narrow angle or a history of acute attacks of glaucoma • eye infection or inflammation in the 3 months preceding the screening visit • eye surgery, or argon laser trabeculoplasty in the last three months. • History of hypersensitivity to benzalkonium chloride or other components contained in the formulation of study drug • Use of topical drugs that may interfere with the study medication • Causes of secondary increase of intraocular pressure • Contraindications to the use of systemic drugs in the studio

Investigators

Sponsor
IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS

Similar Trials

Completed
Phase 3
Efficacy and safety of bimatoprost 0.01% for the treatment of eyebrow hypotrichosis: A randomized&#44; double&#45;blind&#44; vehicle&#45;controlled studyEyebrow hypotrichosisMadarosis
TCTR20160911001Division of Dermatology&#44; Ramathibodi Hospital&#44; Mahidol University40
Completed
Not Applicable
Comparable study between bimatoprost and latanoprost/timolo fixed combination in primary open angle glaucoma patientsPrimary open angle glaucoma patients
JPRN-UMIN000004595Department of Ophthalmology, Kyoto Prefectural University of Medicine80
Active, not recruiting
Phase 1
The Efficacy and Safety of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular HypertensioOpen-angle Glaucoma and Ocular HypertensionMedDRA version: 18.0 Level: HLGT Classification code 10018307 Term: Glaucoma and ocular hypertension System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: PT Classification code 10030043 Term: Ocular hypertension System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: PT Classification code 10030348 Term: Open angle glaucoma System Organ Class: 10015919 - Eye disorders
EUCTR2014-003037-26-ESAllergan Limited600
Active, not recruiting
Phase 1
The Efficacy and Safety of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular Hypertensio
EUCTR2014-003037-26-HUAllergan Limited600
Active, not recruiting
Phase 1
The Efficacy and Safety of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular HypertensioOpen-angle Glaucoma and Ocular HypertensionMedDRA version: 20.0 Level: HLGT Classification code 10018307 Term: Glaucoma and ocular hypertension System Organ Class: 100000004853MedDRA version: 20.0 Level: PT Classification code 10030043 Term: Ocular hypertension System Organ Class: 10015919 - Eye disordersMedDRA version: 20.0 Level: PT Classification code 10030348 Term: Open angle glaucoma System Organ Class: 10015919 - Eye disorders
EUCTR2014-003037-26-ATAllergan Limited600